influenzae Type B Infections - Therapeutics under Development by Companies 11
influenzae vaccine introduced in all national immunization programmes.
After culturing, Streptococcus pneumoniae, Haemophilus
influenza, Moraxella catarrhalis, and Staphylococcus aureus were observed in 35, 54, 13, and 2 cases, respectively, and culture results were negative in 49 cases.
Functional characterization of human lgG, lgM, lgA antibody directed to the capsule of Haemophilus
influenzae type b.
Reclassification of Actinobacillus actinomycetecomitans, Haemophilus
paraphrophilus and Haemophilus
segnis as Aggregatibacter actinomycetecomitans gen.
Detection of bacterial DNA in cerebrospinal fluid by an assay for simultaneous detection of Neisseria meningitidis, Haemophilus
influenzae, and streptococci using a seminested PCR strategy.
The report provides a snapshot of the global therapeutic landscape of Haemophilus
influenzae Type B Infections
Licensure of a Haemophilus
influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine.
Keywords: Adhesins, Haemophilus
influenza, HMW1 protein
Patients with asplenia are at significant increased risk of sepsis due to encapsulated bacteria, such as Haemophilus
The report reviews key players involved in the therapeutics development for Haemophilus
Influenzae Type b Infections and enlists all their major and minor projects
Protective antibody levels were not found for certain strains of polio and Streptococcus pneumonia, and Haemophilus